$181.97-0.10 (-0.06%)
DaVita Inc.
DaVita Inc. in the Healthcare sector is trading at $181.97 with a market capitalization of $11.2B. Wall Street consensus targets $219.86 (7 analysts), implying a +20.8% move over the next 12 months. The stock is currently 26% below its 52-week high of $247.49, remaining 5.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.55B↑ | $3.42B↓ | $3.62B↑ | $3.42B↑ | $3.38B |
| Gross Profit | $1.16B↑ | $1.07B↓ | $1.21B↑ | $1.09B↓ | $1.12B |
| Operating Income | $570.82M↑ | $473.55M↓ | $551.21M↑ | $495.61M↓ | $530.48M |
| Net Income | $265.40M↑ | $197.53M↓ | $234.22M↑ | $150.33M↓ | $199.34M |
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpa...
Academic risk and quality models computed from DVA's own filings and price history, not from analyst opinion.
Mixed: 6 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z below 1.81, the financial-distress band. This measures balance-sheet stress, not share-price direction.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 37.9% reading.
Fama-French 5-factor market beta. The five factors explain 10% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.